$AVXL 8-K SEC Filings

Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs

Anavex now has open INDs in all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome

As further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. (“Anavex” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on September 24, 2026. The election of th...

As previously disclosed, Anavex Life Sciences Corp. (“Anavex” or the “Company”) is prioritizing the advancement of its ANAVEX®2-73 (blarcamesine) clinical development pipeline in early Alzheimer’s disease, Rett syndrome and Fragile X syn...